NASDAQ: ADAGAdagene Inc Stock
$2.73+0.09 (+3.41%)
Updated Apr 22, 2024
ADAG Price
$2.73
Fair Value Price
N/A
Market Cap
$120.44M
52 Week Low
$1.10
52 Week High
$4.38
P/E
-6.25x
P/B
1.71x
P/S
4.67x
PEG
N/A
Dividend Yield
N/A
Revenue
$18.11M
Earnings
-$18.95M
Gross Margin
100%
Operating Margin
-89.15%
Profit Margin
-104.6%
Debt to Equity
0.64
Operating Cash Flow
-$28M
Beta
0.38
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ADAG Overview
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ADAG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ADAG is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ADAG is good value based on its book value relative to its share price (1.71x), compared to the US Biotechnology industry average (5.82x)
P/B vs Industry Valuation
ADAG is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ADAG due diligence checks available for Premium users.
Be the first to know about important ADAG news, forecast changes, insider trades & much more!
ADAG News
Valuation
ADAG price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.25x
Industry
16.21x
Market
41x
ADAG price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.71x
Industry
5.82x
ADAG is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ADAG's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
ADAG's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ADAG's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$115.7M
Liabilities
$45.2M
Debt to equity
0.64
ADAG's short-term assets ($113.44M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ADAG's short-term assets ($113.44M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ADAG's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ADAG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
ADAG's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ADAG vs Biotech Stocks
Adagene Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.